Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Puma Biotechnology, Inc.
< Previous
1
2
3
Next >
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
April 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
March 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
February 13, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
January 11, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
December 11, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
October 19, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
October 14, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
September 21, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
August 08, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Second Quarter Financial Results
August 03, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
July 20, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
June 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports First Quarter Financial Results
May 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
April 20, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
March 14, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
March 02, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
February 28, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.